کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
8208956 1532081 2016 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant
موضوعات مرتبط
مهندسی و علوم پایه فیزیک و نجوم تشعشع
پیش نمایش صفحه اول مقاله
A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant
چکیده انگلیسی
Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies - 90Y-ibritumomab tiuxetan is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling 131I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling 131I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose 131I-rituximab (6000 MBq/163 mCi) combined with BEAM conditioning for autologous HSCT.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Applied Radiation and Isotopes - Volume 116, October 2016, Pages 13-21
نویسندگان
, , , , , , ,